Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBITDA: 2021-2025

Historic EBITDA for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$50.5 million.

  • Prime Medicine's EBITDA rose 3.60% to -$50.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.3 million, marking a year-over-year increase of 9.93%. This contributed to the annual value of -$195.9 million for FY2024, which is 0.96% up from last year.
  • Latest data reveals that Prime Medicine reported EBITDA of -$50.5 million as of Q3 2025, which was up 3.89% from -$52.6 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's EBITDA registered a high of -$16.4 million during Q3 2021, and its lowest value of -$65.5 million during Q4 2023.
  • In the last 3 years, Prime Medicine's EBITDA had a median value of -$50.6 million in 2023 and averaged -$49.9 million.
  • The largest annual percentage gain for Prime Medicine's EBITDA in the last 5 years was 37.69% (2022), contrasted with its biggest fall of 80.96% (2022).
  • Prime Medicine's EBITDA (Quarterly) stood at -$62.9 million in 2021, then soared by 37.69% to -$39.2 million in 2022, then plummeted by 67.06% to -$65.5 million in 2023, then spiked by 35.43% to -$42.3 million in 2024, then rose by 3.60% to -$50.5 million in 2025.
  • Its last three reported values are -$50.5 million in Q3 2025, -$52.6 million for Q2 2025, and -$51.9 million during Q1 2025.